Clinical assessment of visual outcomes and safety in Indian cataract patients implanted with the Optiflex Trio trifocal intraocular lens.

PURPOSE: This study evaluates the performance and safety of the Optiflex Trio trifocal intraocular lens (IOLs) in Indian cataract patients.

DESIGN

Single-arm prospective clinical study.

METHODS

Patients undergoing phacoemulsification for senile cataracts received bilateral Optiflex Trio trifocal IOLs. Visual outcomes, spherical equivalent, reading performance, contrast sensitivity, stereo acuity, and high-order aberrations were assessed at 1 week, 1 month, 3 months, 6 months, and 12 months.

RESULTS

A total of 93 eyes were implanted with IOL and showed significant improvement from pre-op to 12 months in the uncorrected distance (UDVA: 0.74 ± 0.33 to 0.01 ± 0.04 logMAR, P = 0.0001), intermediate (UIVA: 0.62 ± 0.20 to 0.01 ± 0.03 logMAR, P = 0.0001) and near visual acuity (UNVA: 0.57 ± 0.20 to 0.01 ± 0.02 logMAR, P = 0.0001), best-corrected distance visual acuity (BCDVA: 0.45 ± 0.29 to 0.00 ± 0.01 logMAR, P = 0.0001), and distance-corrected visual acuities (DCIVA and DCNVA: 0.32 ± 0.23 to 0.00 logMAR, P = 0.0001). The contrast sensitivity increased from 0.52 ± 0.40 to 1.49 ± 0.05 ( P = 0.0001), while high-order and total aberrations decreased (0.87 ± 0.71 to 0.16 ± 0.11 µm and 1.55 ± 1.13 to 0.21 ± 0.07 µm, both P = 0.0001). Near/intermediate reading speeds improved by 5.18 ± 8.72 and 5.15 ± 8.72 words/min ( P = 0.000). Stereo acuity significantly enhanced, with FD2 from 265.14 ± 124.93 to 83.41 ± 12.56 and Near Radnor from 211.71 ± 114.60 to 74.77 ± 6.98 ( P < 0.0001). No adverse events were reported.

CONCLUSION

Optiflex Trio trifocal IOL enhances vision, reduces aberrations, and supports spectacle independence.